losartan has been researched along with Nephrotic Syndrome in 21 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure." | 9.14 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010) |
| "To study the effects of the angiotensin II receptor antagonist losartan on the lipid profile of patients with nephrotic range proteinuria." | 9.08 | Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. ( de Jong, PE; de Zeeuw, D; Dullaart, RP; Gansevoort, RT, 1995) |
| " After the stabilization of proteinuria at the sixth week, the rats were treated for 6 weeks by losartan (n = 10, 30 mg/kg/day), HBO (n = 10, 2." | 7.73 | Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. ( Acikel, C; Aktug, H; Caglar, K; Eyileten, T; Ikizler, TA; Kaya, A; Korkmaz, A; Oguz, Y; Oter, S; Sonmez, A; Topal, T; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2006) |
| "We compared the effect of an ACE inhibitor, enalapril, and an angiotensin II antagonist, losartan, on total malodialdehyde in blood and the urinary excretion of certain eicosanoids and their metabolites (TxB(2), 6-keto-PGF(1alpha), bicyclo-PGE(2) and 8-isoprostane) in experimental adriamycin-induced nephrotic syndrome in rats." | 7.71 | Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. ( Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 2002) |
| " daily for 3 weeks) and angiotensin II antagonist (losartan, 2 mg/kg bw in the same way) on experimental nephrotic syndrome induced in rats by the administration of adriamycin (5 mg/kg bw i." | 7.70 | [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. ( Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 1999) |
| "Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure." | 5.14 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010) |
| "To study the effects of the angiotensin II receptor antagonist losartan on the lipid profile of patients with nephrotic range proteinuria." | 5.08 | Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. ( de Jong, PE; de Zeeuw, D; Dullaart, RP; Gansevoort, RT, 1995) |
| " She had been taking losartan tablets before and during pregnancy." | 4.02 | Use of angiotensin II receptor blocker during pregnancy: A case report. ( Duan, MF; Huang, N; Song, CR; Wang, YM; Wei, Q; Zhang, L, 2021) |
| " After the stabilization of proteinuria at the sixth week, the rats were treated for 6 weeks by losartan (n = 10, 30 mg/kg/day), HBO (n = 10, 2." | 3.73 | Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. ( Acikel, C; Aktug, H; Caglar, K; Eyileten, T; Ikizler, TA; Kaya, A; Korkmaz, A; Oguz, Y; Oter, S; Sonmez, A; Topal, T; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2006) |
| "We compared the effect of an ACE inhibitor, enalapril, and an angiotensin II antagonist, losartan, on total malodialdehyde in blood and the urinary excretion of certain eicosanoids and their metabolites (TxB(2), 6-keto-PGF(1alpha), bicyclo-PGE(2) and 8-isoprostane) in experimental adriamycin-induced nephrotic syndrome in rats." | 3.71 | Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. ( Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 2002) |
| "The effect of type 1 angiotensin II receptor antagonist treatment (losartan) on cardiac baroreflex regulation of renal sympathetic nerve activity (RSNA) and renal sodium handling in rats with nephrotic syndrome was examined." | 3.70 | Role of angiotensin in renal sympathetic activation in nephrotic syndrome. ( DiBona, GF; Jones, SY; Sanchez-Palacios, M, 1998) |
| " daily for 3 weeks) and angiotensin II antagonist (losartan, 2 mg/kg bw in the same way) on experimental nephrotic syndrome induced in rats by the administration of adriamycin (5 mg/kg bw i." | 3.70 | [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. ( Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 1999) |
| "We explored the role of angiotensin II and vasopressin in the maintenance of blood pressure during the nephrotic syndrome of adriamycin-induced nephropathy in rats." | 3.69 | Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats. ( Ferrari-Spadotto, A; Franco, R; Gavras, H; Gavras, I; Georgette, J; Gut, A, 1994) |
| "With treatment of prednisolone, an angiotensin-converting enzyme inhibitor, and an angiotensin II receptor-blocker, his proteinuria markedly decreased and renal function was stabilized." | 2.43 | Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. ( Gejyo, F; Hiura, T; Kawabe, S; Miyamura, S; Nishi, S; Saeki, T; Ueno, M; Yamazaki, H, 2006) |
| "Losartan 50 mg/d was used to control proteinuria under the close watch of serum creatinine." | 1.51 | [The 467th case: proteinuria, periungual fibromas, and facial steatadenomas]. ( Chen, G; Dong, QR; Li, MX; Li, XM, 2019) |
| "Treatment with enalapril for 2 years (0." | 1.35 | Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment. ( Devriendt, K; Proesmans, W; Van Dyck, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, Q | 1 |
| Zhang, L | 1 |
| Duan, MF | 1 |
| Wang, YM | 1 |
| Huang, N | 1 |
| Song, CR | 1 |
| Chen, G | 1 |
| Dong, QR | 1 |
| Li, MX | 1 |
| Li, XM | 1 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Eroglu, E | 1 |
| Unal, A | 1 |
| Sipahioglu, MH | 1 |
| Berk, V | 1 |
| Tokgoz, B | 1 |
| Oymak, O | 1 |
| Mohapatra, A | 1 |
| Matthai, SM | 1 |
| Vijayakumar, K | 1 |
| Basu, G | 1 |
| de Zeeuw, D | 1 |
| Gansevoort, RT | 1 |
| Dullaart, RP | 1 |
| de Jong, PE | 1 |
| Proesmans, W | 1 |
| Van Dyck, M | 1 |
| Devriendt, K | 1 |
| Akman, S | 1 |
| Kalay, S | 1 |
| Akkaya, B | 1 |
| Koyun, M | 1 |
| Akbaş, H | 1 |
| Baysal, YE | 1 |
| Guven, AG | 1 |
| Kosmadakis, G | 1 |
| Filiopoulos, V | 1 |
| Georgoulias, C | 1 |
| Tentolouris, N | 1 |
| Michail, S | 1 |
| Kondo, S | 1 |
| Urushihara, M | 1 |
| Kagami, S | 1 |
| Grosch, S | 1 |
| Van Overmeire, L | 1 |
| Krzesinski, JM | 1 |
| Bovy, C | 1 |
| Saeed, B | 1 |
| Mazloum, H | 1 |
| Askar, M | 1 |
| Lehnhardt, A | 1 |
| Lama, A | 1 |
| Amann, K | 1 |
| Matejas, V | 1 |
| Zenker, M | 1 |
| Kemper, MJ | 1 |
| Nakhoul, F | 1 |
| Ramadan, R | 1 |
| Khankin, E | 1 |
| Yaccob, A | 1 |
| Kositch, Z | 1 |
| Lewin, M | 1 |
| Assady, S | 1 |
| Abassi, Z | 1 |
| Bökenkamp, A | 1 |
| deJong, M | 1 |
| van Wijk, JA | 1 |
| Block, D | 1 |
| van Hagen, JM | 1 |
| Ludwig, M | 1 |
| Yilmaz, MI | 1 |
| Korkmaz, A | 1 |
| Kaya, A | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Topal, T | 1 |
| Eyileten, T | 1 |
| Yenicesu, M | 1 |
| Acikel, C | 1 |
| Oter, S | 1 |
| Yaman, H | 1 |
| Aktug, H | 1 |
| Oguz, Y | 1 |
| Vural, A | 1 |
| Ikizler, TA | 1 |
| Hiura, T | 1 |
| Yamazaki, H | 1 |
| Saeki, T | 1 |
| Kawabe, S | 1 |
| Ueno, M | 1 |
| Nishi, S | 1 |
| Miyamura, S | 1 |
| Gejyo, F | 1 |
| Franco, R | 1 |
| Gut, A | 1 |
| Ferrari-Spadotto, A | 1 |
| Georgette, J | 1 |
| Gavras, I | 1 |
| Gavras, H | 1 |
| Sanchez-Palacios, M | 1 |
| Jones, SY | 1 |
| DiBona, GF | 1 |
| Amuchastegui, SC | 1 |
| Azzollini, N | 1 |
| Mister, M | 1 |
| Pezzotta, A | 1 |
| Perico, N | 1 |
| Remuzzi, G | 1 |
| Tesar, V | 2 |
| Zima, T | 2 |
| Jirsa, M | 2 |
| Crkovská, J | 2 |
| Stípek, S | 2 |
| Vernerová, Z | 2 |
| Seráková, M | 2 |
2 reviews available for losartan and Nephrotic Syndrome
| Article | Year |
|---|---|
[Progress of pediatric nephrology].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antibodies, Monoclonal, Murine-Derived; Bio | 2011 |
Nephrotic syndrome and IgA nephropathy in polycystic kidney disease.
Topics: Aged; Biopsy; Dipyridamole; Glomerulonephritis, IGA; Humans; Kidney; Losartan; Male; Nephrotic Syndr | 2006 |
2 trials available for losartan and Nephrotic Syndrome
| Article | Year |
|---|---|
Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apolipoprotein A-I; Apolipoproteins | 1995 |
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2010 |
17 other studies available for losartan and Nephrotic Syndrome
| Article | Year |
|---|---|
Use of angiotensin II receptor blocker during pregnancy: A case report.
Topics: Adult; Angiotensin Receptor Antagonists; Female; Humans; Losartan; Nephrotic Syndrome; Oligohydramni | 2021 |
[The 467th case: proteinuria, periungual fibromas, and facial steatadenomas].
Topics: Angiomyolipoma; Apolipoprotein L1; Creatinine; Female; Glomerulonephritis, IGA; Humans; Kidney Failu | 2019 |
Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma.
Topics: Adenocarcinoma; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Edema; Glomerulonephri | 2013 |
Quiz page: an unusual cause of nephrotic syndrome.
Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension | 2015 |
Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Com | 2009 |
Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Enalapril; | 2009 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; G | 2011 |
Spontaneous remission of post-transplant recurrent focal and segmental glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Pr | 2011 |
Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR.
Topics: Abnormalities, Multiple; Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2012 |
Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Doxorubi | 2005 |
R561C missense mutation in the SMARCAL1 gene associated with mild Schimke immuno-osseous dysplasia.
Topics: Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Angiotensin II Type 1 Receptor Bloc | 2005 |
Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model.
Topics: Animals; Doxorubicin; Drug Synergism; Hyperbaric Oxygenation; Kidney; Losartan; Male; Nephrotic Synd | 2006 |
Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Doxorubicin; H | 1994 |
Role of angiotensin in renal sympathetic activation in nephrotic syndrome.
Topics: Angiotensin II; Animals; Baroreflex; Blood Pressure; Body Weight; Heart Rate; Infusions, Intravenous | 1998 |
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Chronic Disease; Dihydropyridines; Disease | 1998 |
[Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dinoprost; Doxorubicin; Eicosanoi | 1999 |
Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dinoprost; Enalapril; F2-Isoprost | 2002 |